Celgene Options Four Immunotherapy Candidates from Dragonfly; Deal Expanded to Eight Targets; BMS Exercises Five I-O Options so Far
Celgene Corp. paid $33mm up front for an exclusive option to license global rights to up to four of Dragonfly Therapeutics Inc.’s immuno-oncology projects.
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.